ARUN CHANDAVARKAR
Biocon Biologics appoints Shreehas Tambe as MD & CEO
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build and shape Biocon’s biosimilars business and spearheaded the Group’s strategic capital investments, including its first overseas facility in Malaysia. He has also been instrumental in securing regulatory approvals and enabling the successful launch of several of the Company’s biosimilar assets in global markets such as the U.S. and EU.
Biocon Biologics interchangeable insulin Semglee gets US FDA approval
Biocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in the United States to treat diabetic patients.
Biocon Biologics provided 7,000 doses of Itolizumab in April
The company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new biosimilar launches in both emerging and developed markets, Arun Chandavarkar, managing director of Biocon Biologics, told ET in an interview.
Biocon founder Kiran Mazumdar Shaw hails expert panel’s nod to Sputnik V
“It adds to our armoury. I hope it is one more step towards vaccinating the general population,” Shaw told ET on hearing the news about a third vaccine making its way into India. Health authorities in India are currently using Bharat Biotech’s Covaxin and Oxford’s Covishield to vaccinate eligible people.
Biocon Biologics promotes Shreehas Tambe as deputy CEO
A Biocon veteran, Shreehas Tambe joined the company in 1997 and has more than 20 years of leadership experience in operational and strategic roles.
Buy Biocon, price target Rs 325: Kunal Bothra
The analyst suggested a stoploss at Rs 302.
- Go To Page 1
Buy Biocon, price target Rs 311: Jay Thakkar
The analyst suggested a stoploss at Rs 296.
Citigroup has buy on Biocon, target price Rs 350
Citi gave the buy rating after the company and Mylan announced launch of Ogivri in the US.
Biocon elevates Siddharth Mittal as CEO and joint MD
Mittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30.
Biocon reports 64% jump in Q4 net riding on biologics
Biocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.
Buy Biocon, target Rs 660: Manas Jaiswal
Buy Biocon Ltd. at a price target of Rs 660.0 and a stop loss at Rs 630 from the entry point.
Buy Biocon, target Rs 625: Manas Jaiswal
Buy Biocon Ltd. at a price target of Rs 625.0 and a stop loss at Rs 594 from entry point.
Buy Biocon, target Rs 668: Kunal Bothra
Buy Biocon Ltd. at a price target of Rs 668.0 and a stop loss at Rs 622 from entry point.
Buy Biocon, target Rs 642: Jay Thakkar
Buy Biocon Ltd. at a price target of Rs 642.0 and a stop loss at Rs 606 from entry point.
Buy Biocon, target Rs 641: Dr CK Narayan
Buy Biocon Ltd. at a price target of Rs 641.0 and a stop loss at Rs 620 from entry point.
Mylan-Biocon's breast cancer biosimilar gets ANVISA nod
Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.
Biocon shares gain on updates on proposed biosimilars Trastuzumab and Pegfilgrastim
On the BSE, 1.61 lakh shares were traded on the counter so far in the trade.
Biocon introduces oncologic biosimilar KRABEVA in India
The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India.
See full recovery from GST impact in second half of 2017: Arun Chandavarkar, Biocon
In order to recover in terms of to compensate or offset these costs through revenues in Malaysia we had guided that as and when initially we start receiving emerging market approvals in Malaysia
Biocon surges on USFDA's cancer drug approval
For the quarter ended March 31, 2017, Biocon reported total revenue at Rs 632.10 crore and net profit stood at 203.80 crore.
Buy Biocon Ltd. target Rs 1234.0 : Rakesh Bansal
Buy Biocon Ltd. at a price target of Rs 1234.0 and a stoploss at Rs 1107.0 from entry point
Mylan and Biocon make USFDA submission for proposed biosimilar trastuzumab
The submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data that consists of two pharmacokinetic studies and a confirmatory efficacy and safety trial, Biocon stated in a release.
European Medicines Agency accepts marketing application of Biocon, Mylan product
Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.
EMA accepts marketing application of Biocon, Mylan product
Mylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statement.
Biocon, Mylan drug discovery programme to treat cancer, arthritis makes progress
Biocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3 of clinical trials.
Biocon posts 15% rise in revenue, names new CEO
Biocon, the country's largest biotech company, reported a 15% rise in fourth-quarter revenue to 746 crore, helped by a 17% rise in sales at its branded formulation division.
Biocon Q4 Net dips 54 per cent at Rs 113 crore
For the year ended March 31, 2014, the company's net profit declined by 18.69 per cent to Rs 413.72 crore from Rs 508.82 crore in the 2012-13 fiscal.
Biocon joins hands with US co Amylin for diabetes drug
Biocon has put the development of its diabetes drug on the fast track by teaming up with US-based biopharma player Amylin Pharmaceuticals.
Clinical trials for oral insulin to enter phase two: Biocon
After the success of its recomibant human insulin "Insugen", Biocon said clinical trials for the oral insulin would soon enter phase two.
Load More
